Company Overview: Bioline RX Ltd.

Industry News

27 Mar

BioLineRx’s AGI-134 to be Presented at AACR 2017

Tel Aviv, Israel – March 27, 2017 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that AGI-134,  an immunotherapy for the treatment of multiple cancers, obtained through its recently announced acquisition of Agalimmune Ltd., will be featured at the upcoming American...

Read more

23 Mar

BioLineRx Announces Acquisition of Agalimmune Ltd. to Accelerate Expansion of Immuno-Oncology Pipeline

TEL AVIV, Israel, March 23, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it has acquired Agalimmune Ltd., a private UK-based company with an innovative, anti-cancer immunotherapy platform. Acquisition consideration consisted of a $6 million upfront payment, of...

Read more

23 Mar

BioLineRx Reports Year End 2016 Financial Results

TEL AVIV, Israel, March 23, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX,  TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the year ended December 31, 2016. Highlights and achievements in 2016 and to date: Acquired Agalimmune Ltd., a UK-based biopharmaceutical company...

Read more

16 Mar

BioLineRx to Report Annual 2016 Results on March 23, 2017

TEL AVIV, Israel, March 16, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its audited annual financial results for the year ended December 31, 2016 on Thursday, March 23, 2017, before the US markets open. The Company will...

Read more

17 Jan

BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA® for Pancreatic Cancer

TEL AVIV, Israel, January 17, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the initiation of a second Phase 2a trial investigating BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients...

Read more

4 Jan

BioLineRx to Present at Biotech Showcase 2017 Conference in San Francisco

TEL AVIV, Israel, January 4, 2017 /PRNewswire/ — BioLineRx (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Philip Serlin, will be presenting at the Biotech Showcase 2017 Conference being held in San Francisco, CA. The...

Read more

5 Dec

BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016

TEL AVIV, Israel, December 5, 2016 /PRNewswire/ — BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase 2a correlative data, as well as detailed mechanism-of-action data, for BL-8040, the Company’s leading oncology platform at the ongoing 58th American...

Read more

22 Nov

BioLineRx Reports Third Quarter 2016 Financial Results

TEL AVIV, Israel, Nov. 22, 2016 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, today reports its financial results for the third quarter ended September 30, 2016. Highlights and achievements during third quarter of 2016 and to...

Read more

Page 1 of 712345...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address